Search for information about a product,
therapeutic area or event

Media, investors, advocacy organizations and others, please contact us here.

PROTECT Post Hoc Analysis: Efficacy of Sparsentan (SPAR) vs Irbesartan (IRB) in Patients (Pts) With IgA Nephropathy ≤12 mo vs >12 mo From Kidney Biopsy

Page 1 / 1 100%
Loading...